Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Clin Pharm Ther ; 43(1): 159-162, 2018 Feb.
Article in English | MEDLINE | ID: mdl-29114905

ABSTRACT

WHAT IS KNOWN AND OBJECTIVE: Literature evidence suggests leukotriene involvement in the pathogenesis of atopic dermatitis. This article aimed to discuss whether the off-label use of montelukast, a leukotriene receptor antagonist, is justifiable for the treatment of atopic dermatitis. COMMENT: Most non-randomized studies supported the use of montelukast for atopic dermatitis treatment. However, evidence from these studies should be interpreted with caution as it is relatively weak due to the absence of randomization, control groups and blinding processes, subjecting the results to high risk of selection and reporting biases. The inconsistent findings across RCTs may be related to the limited number of patients, nuances in study designs, varying severity of disease and the concomitant use of steroids in some of the studies. WHAT IS NEW AND CONCLUSION: Current literature evidence is limited to rationally support the use of montelukast in atopic dermatitis treatment. For now, the conventional treatments should be preferred in the clinical setting.


Subject(s)
Dermatitis, Atopic/drug therapy , Leukotriene Antagonists/therapeutic use , Acetates/therapeutic use , Cyclopropanes , Humans , Quinolines/therapeutic use , Randomized Controlled Trials as Topic , Sulfides , Treatment Outcome
2.
Radiat Prot Dosimetry ; 99(1-4): 295-302, 2002.
Article in English | MEDLINE | ID: mdl-12194311

ABSTRACT

Using a model system of in vitro human peripheral blood lymphocytes, the effect of low-dose (0.25 to 1.50 Gy) 250-kVp X ray radiation (1 Gy.min-1) on the expression of several proto-oncogenes was examined (c-Haras, c-src, c-met, c-jun, c-fos, and c-myc) and beta-actin from 0.25 to 17 h post-radiation. RNA was extracted from cells harvested at various times after exposure and examined for levels of particular mRNAs by northern blot hybridisation. A progressive time- and dose-dependent increase in mRNA levels was observed for c-Haras mRNA, while the other proto-oncogenes (c-src, c-met, c-fos, c-jun and c-myc) examined were variable during the same time period. beta-actin levels were initially decreased but at 17 h post-radiation had returned to control levels. A comparison of the rate of c-Haras transcription at 5 and 17 h post-irradiation revealed that c-Haras transcription was higher at 5 h than at 17 h. These findings suggest that the level of specific proto-oncogene expression, particularly c-Haras, may be useful early diagnostic molecular biomarkers for biodosimetry applications. The use of real-time PCR technologies to quantify gene expression changes will also be discussed.


Subject(s)
Gene Expression Regulation/radiation effects , Lymphocytes/radiation effects , Proto-Oncogenes/radiation effects , Radiometry/methods , Cell Nucleus/genetics , Cell Nucleus/radiation effects , Cells, Cultured , Dose-Response Relationship, Radiation , Humans , Predictive Value of Tests , Proto-Oncogene Mas , Transcription, Genetic/radiation effects , X-Rays
SELECTION OF CITATIONS
SEARCH DETAIL
...